TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Celecoxib
PubChem CID 2662
Molecular Weight 381.4g/mol
Synonyms

celecoxib, 169590-42-5, Celebrex, Celebra, Onsenal, Celecox, Celocoxib, 184007-95-2, Xilebao, SC-58635, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide, YM177, 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE, SC 58635, YM 177, HSDB 7038, Celecoxibum, p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide, UNII-JCX84Q7J1L, 194044-54-7, DFN15, JCX84Q7J1L, MFCD00941298, 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, NSC-719627, NSC-758624, SC58635, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide, ELYXYB, CCRIS 9330, DFN-15, DTXSID0022777, CHEBI:41423, Celecoxib (GMP Like), YM-177, CHEMBL118, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonami de, DTXCID502777, CONSENSI COMPONENT CELECOXIB, 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, NSC719627, NSC 719627, NSC 758624, Celecoxib [USAN], NCGC00091455-01, CELECOXIB (MART.), CELECOXIB [MART.], 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide, CELECOXIB (USP-RS), CELECOXIB [USP-RS], CELECOXIB (EP MONOGRAPH), CELECOXIB [EP MONOGRAPH], CELECOXIB (USP MONOGRAPH), CELECOXIB [USP MONOGRAPH], Solexa, Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-, Benzenesulfonamide,4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex (TN), SMR000550473, CAS-169590-42-5, SR-01000837528, Celecixib, Celecoxib [USAN:INN:BAN], Generic Drug, ELYXYB-celecoxib, TPI-336, Celecoxib 50 mg, Celecoxib- Bio-X, Onsenal (TN), AI-525, Celecoxib 100 mg, Celecoxib 200 mg, Celecoxib 400 mg, CEP-33222, CELEBCOXIB, Spectrum_000432, 1oq5, CELECOXIB [INN], CELECOXIB [JAN], CELECOXIB [MI], CELECOXIB [HSDB], Spectrum2_001576, Spectrum3_001996, Spectrum4_000182, Spectrum5_001324, CELECOXIB [VANDF], CELECOXIB [WHO-DD], cid_2662, SCHEMBL3708, Celecoxib (JAN/USP/INN), BSPBio_003596, CELECOXIB [EMA EPAR], KBioGR_000723, KBioGR_002351, KBioSS_000912, KBioSS_002354, MLS001165684, MLS001195656, MLS001304708, MLS006011862, BIDD:GT0408, DivK1c_000893, SPECTRUM1503678, SPBio_001512, GTPL2892, CELECOXIB [ORANGE BOOK], Celecoxib, >=98% (HPLC), BDBM11639, HMS502M15, KBio1_000893, KBio2_000912, KBio2_002351, KBio2_003480, KBio2_004919, KBio2_006048, KBio2_007487, KBio3_002830, KBio3_003037, EX-A175, L01XX33, M01AH01, cMAP_000027, NINDS_000893, BCPP000290, HMS1922G14, HMS2089L18, HMS2093I07, HMS2234N18, HMS3259L08, HMS3261A14, HMS3373A09, HMS3654H09, HMS3715F11, HMS3867I03, HMS3884M07, HY-14398GL, Pharmakon1600-01503678, ALBB-033772, BCP02156, Tox21_111135, Tox21_201964, Tox21_300599, Tox21_500406, US8741944, Comparative Compound, 4-[5-(p-tolyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide, BBL029086, CCG-39354, NSC758624, s1261, STL373576, Celecoxib 1.0 mg/ml in Acetonitrile, AKOS015842517, CELECOXIB COMPONENT OF CONSENSI, Tox21_111135_1, AC-4228, AM84588, BCP9000507, CS-0570, DB00482, KS-1041, NC00708, SB19318, IDI1_000893, NCGC00091455-02, NCGC00091455-03, NCGC00091455-04, NCGC00091455-05, NCGC00091455-06, NCGC00091455-07, NCGC00091455-08, NCGC00091455-09, NCGC00091455-13, NCGC00254540-01, NCGC00259513-01, NCGC00261091-01, BC164295, BP-30217, HY-14398, NCI60_041049, PHA-00846533, SY064976, SBI-0051875.P002, CJ-016377, CP-598107, UNM-0000305813, C2816, CS-0901612, FT-0601628, FT-0623536, FT-0700357, NS00002556, SW199611-3, PF-00345549, A25046, C07589, D00567, EN300-119504, AB00052396-07, AB00052396-08, AB00052396-09, AB00052396_10, AB00052396_11, Q408801, J-010566, J-520011, Q-200816, SR-01000837528-2, SR-01000837528-3, BRD-K02637541-001-02-4, BRD-K02637541-001-06-5, Z1258938406, Celecoxib, European Pharmacopoeia (EP) Reference Standard, Celecoxib, United States Pharmacopeia (USP) Reference Standard, 4-[5-(p-Tolyl)-3-(trifluoromethyl)-1-pyrazolyl]benzenesulfonamide, 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide, 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole, Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyazol-1-yl]benezenesulfonamide, 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
Drug Type Small molecule
Formula C₁₇H₁₄F₃N₃O₂S
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
InChI 1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChIKey RZEKVGVHFLEQIL-UHFFFAOYSA-N
CAS Number 169590-42-5
ChEMBL ID CHEMBL118
ChEBI ID CHEBI:41423
TTD ID D03RTS
Drug Bank ID DB00482
KEGG ID C07589
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 569
Ref_2
Pair Name Zerumbone, Celecoxib
Partner Name Zerumbone
Disease Info [ICD-11: 2B90] Colon cancer Investigative
Biological Phenomena Induction-->Endoplasmic reticulum stress
Gene Regulation Up-regulation Expression ATF3 hsa467
Up-regulation Expression ATF4 hsa468
Up-regulation Cleavage CASP3 hsa836
Up-regulation Expression DDIT3 hsa1649
Up-regulation Phosphorylation EIF2AK3 hsa9451
Up-regulation Phosphorylation EIF2S1 hsa1965
Up-regulation Expression HSPA5 hsa3309
Up-regulation Expression TNFRSF10B hsa8795
In Vitro Model HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens (Human) CVCL_0546
Result Our results provide novel insights into the role of ATF3 as an essential transcription factor for p53-independent DR5 induction upon both ZER and CCB treatment, and this may be a useful biomarker for TRAIL-based anticancer therapy.
Combination Pair ID: 478
Ref_3
Pair Name Tetrahydrocurcumin, Celecoxib
Partner Name Tetrahydrocurcumin
Disease Info [ICD-11: 2C77] Cervical cancer Investigative
Biological Phenomena Inhibition-->Angiogenesis
Gene Regulation Down-regulation Expression EGFR hsa1956
Down-regulation Expression MVD hsa4597
Down-regulation Expression PTGS2 hsa5743
Down-regulation Expression VEGFA hsa7422
In Vitro Model Ca Ski Human papillomavirus-related cervical squamous cell carcinoma Homo sapiens (Human) CVCL_1100
In Vivo Model To evaluate the combinational treatment effect of THC and celecoxib on tumor progression and tumor angiogenesis in cervical cancer (CaSki)-implanted nude mice.
Result The combinational treatment effect of THC and celecoxib causing inhibition of tumor growth and tumor angiogenesis via down-regulation of VEGF, COX-2 and EGFR expression. However, this combined treatment did not show the synergistic effect on inhibiting the tumor growth and tumor angiogenesis in cervical cancer (CaSki)-implanted nude mice model.
Combination Pair ID: 414
Ref_4
Pair Name Salvianolic acid B, Celecoxib
Partner Name Salvianolic acid B
Disease Info [ICD-11: 2C31.Z] Head and neck squamous cell carcinoma Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression COX2 hsa4513
Down-regulation Expression EGFR hsa1956
Up-regulation Expression TP53 hsa7157
In Vitro Model JHU-06 Tongue squamous cell carcinoma Homo sapiens (Human) CVCL_5985
JHU-011 Laryngeal squamous cell carcinoma Homo sapiens (Human) CVCL_5986
JHU-013 Hypopharyngeal squamous cell carcinoma Homo sapiens (Human) CVCL_5988
JHU-022 Laryngeal squamous cell carcinoma Homo sapiens (Human) CVCL_5991
In Vivo Model JHU-013 cells (2×10⁶ cells/100 μl/mouse) were injected subcutaneously into the lower backs of the mice using a 25-gauge needle in left and right sides.
Result These results strongly suggest that combination of Sal-B, a multifunctional anticancer agent, with low-dose celecoxib holds potential as a new preventive strategy in targeting inflammatory-associated tumor development.
Combination Pair ID: 808
Ref_5
Pair Name Resveratrol, Celecoxib
Partner Name Resveratrol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Gene Regulation Down-regulation Expression COX2 hsa4513
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
In Vivo Model Mammary carcinogenesis was initiated with two intra peritoneal doses (50 mg/kg body weight each) of N-methyl-N-nitrosourea (NMU) dissolved in a physiological NaCl solution.
Result This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters. In addition, in terms of tumor volume, the combination was more efficient than celecoxib as a single agent.
Combination Pair ID: 736
Ref_6
Pair Name Plumbagin, Celecoxib
Partner Name Plumbagin
Disease Info [ICD-11: 2C30] Melanoma Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression COX2 hsa4513
Down-regulation Expression STAT3 hsa6774
In Vitro Model UACC-903 Cutaneous melanoma Homo sapiens (Human) CVCL_4052
Mel JuSo Cutaneous melanoma Homo sapiens (Human) CVCL_1403
A375-M Amelanotic melanoma Homo sapiens (Human) CVCL_B222
1205Lu Cutaneous melanoma Homo sapiens (Human) CVCL_5239
In Vivo Model Subcutaneous injection of 1.0×10⁶ UACC 903 or 1205 Lu melanoma cells were injected above both the left and right rib cages of 4-5 week-old female Athymic-Foxn1nu nude mice
Result Combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival.
Combination Pair ID: 847
Ref_7
Pair Name Luteolin, Celecoxib
Partner Name Luteolin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Gene Regulation Up-regulation Expression BAD hsa572
Up-regulation Expression BAK1 hsa578
Up-regulation Expression BAX hsa581
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
SK-BR-3 Breast adenocarcinoma Homo sapiens (Human) CVCL_0033
In Vivo Model MDA-MB-231 cells (2×10⁷) were inoculated subcutaneously into the right flanks of female BALB/c nude mice (6-7 weeks old)
Result These results demonstrate the synergistic anti-tumor effect of the celecoxib and luteolin combination treatment in different four breast cancer cell lines, thus introducing the possibility of this combination as a new treatment modality.
Combination Pair ID: 384
Ref_8
Pair Name Curcumin, Celecoxib
Partner Name Curcumin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Proliferation
Gene Regulation Down-regulation Expression PTGS2 hsa5743
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
Result Our findings show the prominent anti-proliferative effects of celecoxib and/or curcumin on MDA-MB-231 cells, providing a rationale for further detailed preclinical and potential clinical studies of this combination for breast cancer therapy. Further, these computed parameters suggested that curcumin possesses a high tendency to act as an adjuvant drug with celecoxib in the treatment of breast cancer.
Decreasing Drug Toxicity
Hide/Show
Combination Pair ID: 769
Ref_1
Pair Name Honokiol, Celecoxib
Partner Name Honokiol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression FOXM1 hsa2305
Down-regulation Expression FOXP3 hsa50943
Down-regulation Expression ITGAM hsa3684
Down-regulation Expression MKI67 hsa4288
Down-regulation Expression NNT hsa23530
Down-regulation Expression PECAM1 hsa5175
Down-regulation Expression VEGFA hsa7422
In Vitro Model 4T1 Malignant neoplasms of the mouse mammary gland Mus musculus (Mouse) CVCL_0125
Result The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo
03. Reference
No. Title Href
1 Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer. Eur J Pharm Sci. 2020 Apr 15;146:105277. doi: 10.1016/j.ejps.2020.105277. Click
2 Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J Biol Chem. 2014 Aug 1;289(31):21544-61. doi: 10.1074/jbc.M114.558890. Click
3 Combinational Treatment Effect of Tetrahydrocurcumin and Celecoxib on Cervical Cancer Cell-Induced Tumor Growth and Tumor Angiogenesis in Nude Mice. J Med Assoc Thai. 2016 Jul;99 Suppl 4:S23-31. Click
4 Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila). 2010 Jun;3(6):787-96. doi: 10.1158/1940-6207.CAPR-09-0243. Click
5 Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. Eur J Cancer Prev. 2014 Nov;23(6):506-13. doi: 10.1097/CEJ.0000000000000083. Click
6 Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. Cancer Lett. 2017 Jan 28;385:243-250. doi: 10.1016/j.canlet.2016.10.016. Click
7 Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. Tumour Biol. 2015 Aug;36(8):6349-59. doi: 10.1007/s13277-015-3322-5. Click
8 Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer. Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1916-1927. doi: 10.26355/eurrev_202102_25086. Click
It has been 26647 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP